Michael F. Burgess is Head of Research & Development of SpringWorks Therapeutics, Inc.. Currently has a direct ownership of 49,584 shares of SWTX, which is worth approximately $1.64 Million. The most recent transaction as insider was on Jul 18, 2022, when has been sold 3,103 shares (Common Stock) at a price of $28.47 per share, resulting in proceeds of $88,342. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 49.6K
0% 3M change
0% 12M change
Total Value Held $1.64 Million

Michael F. Burgess Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 18 2022
SELL
Payment of exercise price or tax liability
$88,342 $28.47 p/Share
3,103 Reduced 5.89%
49,584 Common Stock
Jun 30 2022
BUY
Grant, award, or other acquisition
-
12,185 Added 18.78%
52,687 Common Stock
Jun 01 2022
SELL
Payment of exercise price or tax liability
$52,398 $19.61 p/Share
2,672 Reduced 6.19%
40,502 Common Stock
Jan 06 2022
BUY
Grant, award, or other acquisition
-
15,674 Added 26.63%
43,174 Common Stock
Jun 01 2021
BUY
Grant, award, or other acquisition
-
27,500 Added 50.0%
27,500 Common Stock

Also insider at

SYBX
SYNLOGIC, INC. Healthcare
TSBX
Turnstone Biologics Corp.
MFB

Michael F. Burgess

Head of Research & Development
Stamford, CT

Track Institutional and Insider Activities on SWTX

Follow SpringWorks Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SWTX shares.

Notify only if

Insider Trading

Get notified when an Spring Works Therapeutics, Inc. insider buys or sells SWTX shares.

Notify only if

News

Receive news related to SpringWorks Therapeutics, Inc.

Track Activities on SWTX